Publications

• Feasibility of evaluating AI-enabled digital symptom monitoring in metastatic patients with NSCLC receiving pembrolizumab therapy: A German single-arm observational pilot study

  Santorelli ML, Schmalz O, Hoiczyk M, Heigener D, Schulte C, Knott M, Hoffknecht P, Vainio J, Burke T, Norquist JM, Riehl S, Hildner A, Barthuber L, Bohnet S

  PMID: 40677515 Show Details link to full text
  Study

  Lung AID

  Year

  2025

  Keywords

  • pembrolizumab

• 45. Titel: Effectiveness of switching to doravirine-based antiretroviral therapy: A real-world study in Germany

  C. Wyen, M. Sabranski, C. Jonsson-Oldenbüttel, J. Bogner, H. Knechten, S. Esser, N. Qurishi, S. Schellberg, I. Kolobova, J.-P. Pelz, Y. O. Whiteside, B. K. Tadese, J. K. Rockstroh

  PMID: 40613664 Show Details link to full text
  Study

  NIS VICDOR

  Year

  2025

  Keywords

• InspeCKD – Analyse zur Prävalenz, Diagnose und Therapie der chronischen Nierenerkrankung

  Christoph Wanner MD, Elke Schaeffner MD, Thomas Frese MD, Ulrich Opfermann MD, Frank Radowsky MD, Philipp Stahl MD, Fabian Burckhardt MD, Felix Scherg MD, Christoph Weber MD & Frederik Mader MD

  PMID: Show Details link to full text
  Study

  InspeCKD

  Year

  2025

  Keywords

  • CKD

• EVOLUTION-HF DEallEF: A non-interventional study of patients with heart failure initiated on dapagliflozin: study design

  Matthias Paul, Ralph Bosch, Behrus Subin, Angelika Guth, Marlena Mueller, Mareike Seelinger, Stephanie Riemann, Birgit Assmus

  PMID: PMC12287773 Show Details link to full text
  Study

  EVOLUTION-HF

  Year

  2025

  Keywords

  • dapagliflozin
  • heart failure

• The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations

  Schaper-Gerhardt, K., Gutzmer, R., Angela, Y., Zimmer, L., Livingstone, E., Schadendorf, D., Hassel, J. C., Weishaupt, C., Remes, B., Kubat, L., Spassova, I., Becker, J. C.

  PMID: 38479119 Show Details link to full text
  Study

  BONEMET

  Year

  2024

  Keywords

  • immunotherapy
  • melanoma

• Design and Rationale of MYOFLAME-19 RCT: MYOcardial protection to reduce inFLAMmatory heart disease due to COVID-19 Infection using CMR Endpoints

  V. O. Puntmann , D. Beitzke, A. Kammerlander, I. Voges, D. D. Gabbert, M. Doerr, B. Chamling, B. Bozkurt, J. C. Kaski, E. Spatz, E. Herrmann, G. Rohde, P. DeLeuw, L. Taylor, C. Windemuth-Kieselbach, C. Harz, M. Santiuste, L. Schoeckel, J. Hirayama, P. C. Taylor, C. Berry, E. Nagel

  PMID: 39481808 Show Details link to full text
  Study

  MYOFLAME-19

  Year

  2024

  Keywords

  • cardiovascular
  • COVID-19

• real-world use of teriflunomide in Germany and changes in treatment patterns over time

  B.-A. Kallmann, G. Zu Eulenburg, J.S. Kullmann, M. Mäurer

  PMID: 38808094 Show Details link to full text
  Study

  TAURUS-MS II

  Year

  2024

  Keywords

  • multiple sclerosis

• InspeCKD - Analysis of the use of diagnostics in patients at high risk for chronic kidney disease in German general practitioner (GP) practices

  C. Wanner, E. Schaeffner, T. Frese, C. Weber, P. Stahl, F. Scherg, F. Burckhardt, U. Opfermann, F. Radowsky, F. Mader

  PMID: 38575833 Show Details link to full text
  Study

  InspeCKD

  Year

  2024

  Keywords

  • CKD

• DETECT IPN: Real-World Experience with Automated Detection of Incidental Pulmonary Nodules in an All-Comer Population

  Johannes Dunsche, Hans-Ulrich Kauczor, Oyunbileg V. Stackelberg, Isabelle Ayx, Rimma Kondrashova, Jens Vogel-Claussen, Joana Lamché, Gerald Schmid-Bindert

  PMID: 10.4236/ojrad.2025.151002 Show Details link to full text
  Study

  DETECT IPN

  Year

  2025

  Keywords

  • lung cancer

• Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial

  E. Livingstone; H. Gogas; L. Kandolf-Sekulovic; F. Meier; T.K. Eigentler; M. Ziemer; P.A.M. Terheyden; A.H. Gesierich; R.A. Herbst; K.C. Kähler; D.C. Ziogas; Z. Mijuskovic; M. Garzarolli; C. Garbe; A. Roesch; S. Ugurel; R. Gutzmer; J.J. Grob; F. Kiecker; J. Utikal; C. Windemuth-Kieselbach; S. Eckhardt; L. Zimmer; D. Schadendorf

  PMID: 10.1016/j.ejca.2023.112941 Show Details link to full text
  Study

  ImmunoCobiVem

  Year

  2023

  Keywords

  • melanoma